Drugs.com - New Drug Approvals

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease

THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related disease...

Apr 14, 2025 - 04:43
 0
Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related disease...
Read More

Tags:

Previous Article

U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipili...

Next Article

Net-Zero by 2050: The IMO’s Victory—and the Case for Less Fuel, Not More

Related Posts

Tevimbra Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Tevimbra Approved in U.S. for First-line Treatment of A...

Mar 5, 2025  0

U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Opdivo (nivo...

Apr 14, 2025  0

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) a...

Apr 14, 2025  0